US equities |
NVDA $233.95 ▲+1.34% MU $1,074.89 ▼-2.05% TSLA $370.59 ▲+4.65% SPCX $158.96 ▲+7.35% SNDK $1,719.99 ▼-3.79% AMD $633.91 ▲+2.95% STX $848.99 ▼-10.21% INTC $119.33 ▼-0.56%
FinancialContent

Harpoon Therapeutics, Inc. - Common Stock (NQ:HARP)

N/A UNCHANGED
Last Price Updated: 4:00 PM EST, Mar 8, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Harpoon Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 Next >
News headline image
Harpoon Therapeutics Provides an Update on the HPN217 Development and Option Agreement with AbbVie
From Harpoon Therapeutics Inc.
Via GlobeNewswire
News headline image
Harpoon Therapeutics Abstract for HPN217 Accepted for Poster Presentation at the 20th International Myeloma Society Annual Meeting
From Harpoon Therapeutics Inc.
Via GlobeNewswire
News headline image
Harpoon Therapeutics to Host KOL Event in Person and via Webcast on September 15, 2023
From Harpoon Therapeutics Inc.
Via GlobeNewswire
News headline image
Harpoon Therapeutics Earnings Perspective: Return On Capital Employed ↗
 
Via Benzinga
Harpoon Therapeutics Earnings Perspective: Return On Capital Employed ↗
 
Via Benzinga
News headline image
Harpoon Therapeutics to Participate in Two Upcoming Investor Conferences in September
From Harpoon Therapeutics Inc.
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Monday's Intraday Session ↗
 
Via Benzinga
News headline image
Harpoon Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update
From Harpoon Therapeutics Inc.
Via GlobeNewswire
News headline image
Harpoon Therapeutics to Participate in Two Upcoming Investor Conferences in August
From Harpoon Therapeutics Inc.
Via GlobeNewswire
News headline image
Harpoon Therapeutics Appoints Haibo Wang as Senior Vice President of Business Development
From Harpoon Therapeutics Inc.
Via GlobeNewswire
News headline image
Harpoon Therapeutics Announces Completion of Planned Patient Enrollment in Phase 1 Study of HPN217 in Relapsed/Refractory Multiple Myeloma
From Harpoon Therapeutics
Via GlobeNewswire
News headline image
3 Penny Stocks with Multibagger Potential for the Second Half of 2023 ↗
If you have patience and a high risk tolerance, here are three penny stocks to watch in 2023 for their multibagger potential. 
Via InvestorPlace
News headline image
Harpoon Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update
From Harpoon Therapeutics
Via GlobeNewswire
News headline image
Short Volatility Alert: Harpoon Therapeutics ↗
On Thursday, shares of Harpoon Therapeuti (NASDAQ: HARP) experienced volatile short activity. After the activity, the stock price went down -1.59% to $0.62. The overall sentiment for HARP has been... 
Via Benzinga
News headline image
Harpoon Therapeutics Presents Preclinical Results for Novel T Cell Engagers HPN217 and HPN328 at AACR 2023
From Harpoon Therapeutics
Via GlobeNewswire
News headline image
Harpoon Therapeutics Presents Data for New ProTriTAC™ Development Candidates in TROP2- and ITGB6-expressing Solid Tumors at AACR 2023
Results support further investigation of two new ProTriTAC™ protease-activated T cell engager development candidates, with demonstrated therapeutic potential in a broad range of TROP2- and... 
From Harpoon Therapeutics
Via GlobeNewswire
News headline image
Harpoon Therapeutics to Participate in the Canaccord Horizons in Oncology Conference
From Harpoon Therapeutics
Via GlobeNewswire
News headline image
Harpoon Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update
From Harpoon Therapeutics
Via GlobeNewswire
News headline image
Harpoon Therapeutics Announces Closing of $25 Million Private Placement
From Harpoon Therapeutics
Via GlobeNewswire
News headline image
Harpoon Therapeutics Announces Acceptance of Five Abstracts for Presentation at AACR Annual Meeting 2023
From Harpoon Therapeutics
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Friday's After-Market Session ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Tuesday's After-Market Session ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Friday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Why Sabre Are Trading Lower By 19%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session ↗
Gainers Sera Prognostics, Inc. (NASDAQ: SERA) shares surged 63.4% to $2.11 after the company announced top-line data from the AVERT PRETERM TRIAL. 
Via Benzinga
News headline image
Harpoon Therapeutics to Participate in the SVB Securities Global Biopharma Conference
From Harpoon Therapeutics
Via GlobeNewswire
News headline image
The 3 Most Undervalued Penny Stocks to Buy in February 2023 ↗
Here are three penny stocks in emerging sectors that look to be undervalued relative to the consensus price target of analysts. 
Via InvestorPlace
News headline image
Why Heart Test Laboratories Are Trading Higher By 136%? Here Are Other Stocks Moving In Monday's Mid-Day Session ↗
Gainers Heart Test Laboratories, Inc. (NASDAQ: HSCS) shares surged 136% to $2.06 after Ascendant Capital initiated coverage on the stock with a Buy rating and a $3.30 price target. 
Via Benzinga
News headline image
Why CN Energy Group Shares Are Trading Lower By 47%; Here Are 20 Stocks Moving Premarket ↗
Gainers BigBear.ai Holdings, Inc. (NYSE: BBAI) shares rose 45.4% to $3.52 in pre-market trading after gaining around 7% on Friday. BigBear.AI recently announced a $25 million private placement. 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Monday's Pre-Market Session ↗
 
Via Benzinga
News headline image
MarketBeat: Week in Review 12/12 - 12/16
A triple-witching day means it could be a rough end to a trading week. Before you step away for the holidays, here are some of the top articles from this week. 
Via MarketBeat
Topics Economy
< Previous 1 2 3 4 5 6 Next >